Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process

You may also be interested in...



China Tops U.S. In Healthcare Expansion Destination But Regulatory Burdens Weigh – Survey

Despite a deepening economic slowdown and ongoing market access challenges, China overtook the U.S. as the top destination for expansion in a survey of global healthcare executives. Meanwhile, the 300-plus executives surveyed by UPS also rank regulatory hurdles above cost as the top barrier to expansion.

Five NCEs Approved In China In 2011: A Closer Look At SFDA’s Progress Report

China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.

China Enhances Data Management, Communication For IND Approvals

The Center for Drug Evaluation is making headway to improve the IND process, but it is still a long road ahead.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel